Sotatercept for treating pulmonary arterial hypertension [ID6163]

Draft guidance: 1

Draft consultation document (online commenting)

Draft guidance (downloadable version) (PDF 247 KB)

Equality impact assessment (downloadable version) (PDF 126 KB)

Committee papers (PDF 6.02 MB)

Final scope (PDF 160 KB)

Final stakeholder list (PDF 154 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 306 KB)

Final scope (PDF 159 KB)

Final stakeholder list (PDF 177 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 306 KB)

Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations, and further details regarding timings and how you can get involved will be available in due course.

Please note that following a call between NICE and the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early June 2024 when we will write to you about how you can get involved.

Please note that following a call between NICE and the company, the timelines for ID6163 - Sotatercept for treating pulmonary arterial hypertension, have been revised. A new invitation to participate will be sent out in January 2025.

Draft matrix post referral (PDF 179 KB)